Abstract-The Ϫ344 C/T and intron 2 conversion variants in the CYP11B2 gene, encoding aldosterone synthase, have been associated with markers of impaired 11␤-hydroxylase activity. We hypothesize that this association is because of variations in the adjacent 11␤-hydroxylase gene (CYP11B1) and arises through linkage disequilibrium between CYP11B1 and CYP11B2. The pattern of variation across the entire CYP11B locus was determined by sequencing 26 normotensive subjects stratified by and homozygous for the Ϫ344 and intron conversion variants. Eighty-three variants associated with Ϫ344 and intron conversion were identified. Haplotype analysis revealed 4 common haplotypes, accounting for 68% of chromosomes, confirming strong linkage disequilibrium across the region. Two novel CYP11B1 polymorphisms upstream of the coding region (Ϫ1889 G/T and Ϫ1859 A/G) were identified as contributing to the common haplotypes. Given the potential for such mutations to affect transcriptional regulation of CYP11B1, these were analyzed further. A total of 512 hypertensive subjects from the British Genetics of Hypertension Study population were genotyped for these polymorphisms. A significant association was identified between the Ϫ1889 polymorphism and urinary tetrahydrodeoxycortisol/total cortisol metabolite ratio, indicating reduced 11␤-hydroxylase efficiency. A similar pattern was observed for the Ϫ1859 polymorphism, but this did not achieve statistical significance. Functional studies in vitro using luciferase reporter gene constructs show that these polymorphisms significantly alter the transcriptional response of CYP11B1 to stimulation by adrenocorticotropic hormone or forskolin. This study strongly suggests that the impaired 11␤-hydroxylase efficiency associated previously with the CYP11B2 Ϫ344 and intron conversion variants is because of linkage with these newly identified polymorphisms in CYP11B1. Key Words: hypertension Ⅲ aldosterone synthase Ⅲ 11␤-hydroxylase Ⅲ polymorphisms Ⅲ transcriptional regulation T he mineralocorticoid hormone aldosterone plays an important role in blood pressure homeostasis. In the Framingham population, plasma aldosterone levels in the top quartile of the normal distribution predicted subsequent rise in blood pressure and future development of hypertension. 1 Furthermore, Յ15% of unselected patients with hypertension have a raised aldosterone/renin ratio, suggesting that altered regulation of aldosterone synthesis or release may be a common factor in essential hypertension. [2] [3] [4] [5] [6] The late stages in aldosterone synthesis that occur in the zona glomerulosa of the adrenal cortex are key in the control of production of the hormone. The 3 terminal steps are a sequential 11␤-hydroxylation, 18-hydroxylation, and 18-oxidation of the precursor 11-deoxycorticosterone, all catalyzed by the enzyme aldosterone synthase. This enzyme is encoded by the CYP11B2 gene, the major regulator of which is angiotensin II. In the zona fasciculata, cortisol is synthesized by a similar pathway, but the final stage is an 11␤-hydroxylation of 11-deoxycortisol (S) by the highly homologous enzyme 11␤-hydroxylase. The CYP11B1 gene, which is controlled by adrenocorticotropic hormone (corticotropin [ACTH]), encodes 11␤-hydroxylase. CYP11B2 and CYP11B1 are situated Ϸ40 kb apart on chromosome 8 in humans. They share 95% sequence similarity, with the main differences being in the 5Ј regions that are responsible for the differences in their transcriptional regulation. 7
T he mineralocorticoid hormone aldosterone plays an important role in blood pressure homeostasis. In the Framingham population, plasma aldosterone levels in the top quartile of the normal distribution predicted subsequent rise in blood pressure and future development of hypertension. 1 Furthermore, Յ15% of unselected patients with hypertension have a raised aldosterone/renin ratio, suggesting that altered regulation of aldosterone synthesis or release may be a common factor in essential hypertension. [2] [3] [4] [5] [6] The late stages in aldosterone synthesis that occur in the zona glomerulosa of the adrenal cortex are key in the control of production of the hormone. The 3 terminal steps are a sequential 11␤-hydroxylation, 18-hydroxylation, and 18-oxidation of the precursor 11-deoxycorticosterone, all catalyzed by the enzyme aldosterone synthase. This enzyme is encoded by the CYP11B2 gene, the major regulator of which is angiotensin II. In the zona fasciculata, cortisol is synthesized by a similar pathway, but the final stage is an 11␤-hydroxylation of 11-deoxycortisol (S) by the highly homologous enzyme 11␤-hydroxylase. The CYP11B1 gene, which is controlled by adrenocorticotropic hormone (corticotropin [ACTH]), encodes 11␤-hydroxylase. CYP11B2 and CYP11B1 are situated Ϸ40 kb apart on chromosome 8 in humans. They share 95% sequence similarity, with the main differences being in the 5Ј regions that are responsible for the differences in their transcriptional regulation. 7 Two common variants have been described previously in the CYP11B2 gene. 8 The first is a single nucleotide substitution from cytosine to thymidine in the 5Ј promoter region (Ϫ344 C/T), which disrupts a putative binding site for the steroidogenic factor 1. The second is an intron conversion in intron 2. This variant exists in 2 alternate forms, either the wild-type (Wt) or the conversion (Conv), where part of intron 2 is replaced by the corresponding intron of the adjacent CYP11B1 gene. These variants are in tight linkage disequilibrium (LD) so that the common haplotypes are T/Conv (38%), C/Wt (45%), and T/Wt (16%). 9 The T allele at Ϫ344 and the Conv allele in intron 2 have been associated previously with hypertension, hypertension with a raised aldosterone/renin ratio, as well as increased levels of aldosterone. 9 -12 However, it should be mentioned that these are not consistent findings, with some studies not seeing any association and others observing an association with the C allele. [13] [14] [15] [16] Interestingly, one consistent reported phenotypic association with the T/Conv haplotype is impaired 11␤-hydroxylase efficiency, indicated by raised ACTH-stimulated levels of the 11-deoxysteroids, 11-deoxycorticosterone and S (which are themselves substrates for the 11␤-hydroxylase enzyme). 17, 18 The molecular mechanism that results in this phenotype is unclear; in vitro reporter gene studies of the Ϫ344 C/T single nucleotide polymorphism (SNP) show no detectable effect on gene transcription, suggesting that this is not the causative variant. 19 Ganapathipillai et al 20 reported that the same biochemical phenotype was associated with a CYP11B1/B2 haplotype that included the Ϫ344 T variant, and it is likely that the Ϫ344 C/T SNP is in LD with causative variants in CYP11B1 that could account for this phenotype. We have reported previously that a SNP in exon 1 (Leu75Leu) of CYP11B1 was strongly associated with the phenotype, 21 but this conservative polymorphism cannot, itself, account for the biochemical change. Accordingly, the aims of the present study were to investigate in detail the pattern of variation across the CYP11B1/CYP11B2 locus to define the precise LD with the Ϫ344 C/T and intron Conv variants. Investigation of the association of 11␤-hydroxylase efficiency with novel CYP11B1 SNPs and also analysis of their effects in vitro was performed to determine the genetic variation responsible for the observed impaired 11␤-hydroxylation.
Methods

Study Subjects
Normal subjects were selected from a World Health Organization survey of cardiovascular risk factors (multinational MONItoring of trends and determinants in CArdiovascular disease [MONICA] IV), which was a random sample of the North Glasgow, Scotland, population. 22 Subjects were aged 36 to 57 years and were normotensive with a fairly narrow blood pressure range (109 to 142 mm Hg systolic and 66 to 90 mm Hg diastolic). Full demographic characteristics of the population and details of blood pressure measurements have been published elsewhere. 22 These subjects had already been genotyped for the Ϫ344 C/T and intron Conv variants. Twenty-six subjects were selected for genetic analysis: TT/ ConvConv (nϭ10), CC/WtWt (nϭ10), and TT/WtWt (nϭ6).
A large hypertensive study population was derived from the Medical Research Council British Genetics of Hypertension (BRIGHT) Study. The BRIGHT Study is a large multicenter investigation into the genetic basis of hypertension, composed of Ͼ2500 affected sibling pairs. Hypertensive subjects were recruited from primary care with entry to the study being dependent on a pretreatment blood pressure of Ͼ145/95 mm Hg (mean of 3 readings). Details of the methods for blood pressure measurements and other demographic characteristics can be found at www.brightstudy.ac.uk. It was aimed to exclude subjects with a body mass index Ͼ30. Full details of the recruitment strategy have been published elsewhere. 23 For the present investigation, we selected a random subgroup of 512 unrelated hypertensive subjects. Full demographic information (as medians and interquartile ranges) on the subjects included is shown in Table 1 . Ϫ1889 numbers: all subjects nϭ437; Ϫ1889GG subjects nϭ116; Ϫ1889GT subjects nϭ223; Ϫ1889TT subjects nϭ98. Ϫ1859 numbers: all subjects nϭ437; Ϫ1859AA subjects nϭ106; Ϫ1859AG subjects nϭ225; Ϫ1859GG subjects nϭ106. NS indicates not significant.
*Comparison between Ϫ1889 GG and TT homozygotes. †Comparison between Ϫ1859 AA and GG homozygotes.
Ethical approval for the study was granted by the local ethics committees of the partner institutes, and fully informed written consent from all of the participants was obtained. All of the procedures were in accordance with institutional guidelines.
Polymorphism Detection
PCR
The nucleotide sequences for human CYP11B1 (accession numbers: D10169, M32863, X85218, M32878, and M32879) and CYP11B2 (accession numbers: D10170, D13752, and M32881) were obtained from the Entrez Nucleotide database. All of the PCRs were performed using Expand High Fidelity PCR system with proofreading capabilities, according to the manufacturer's protocol (Roche Diagnostics). The amplification of CYP11B1 was performed as 2 reactions: from Ϫ2 kb of the 5Ј region to the end of exon 9 (Ϸ7.5 kb) and from the 3Ј region, downstream of the coding region (Ϸ750 bp). The amplification of CYP11B2 was split into 3 separate PCRs: (1) from the 5Ј region to intron 4 (Ϸ5 kb); (2) from exon 5 to exon 9 (Ϸ3 kb); and (3) the 3Ј region, downstream of the coding region (Ϸ1.5 kb). The sequences of the primers (MWG-Biotech) used for these reactions is available in an online supplement at http://hyper. ahajournals.org.
Sequencing
Automated sequencing of the entire region was performed using the ABI Big Dye Terminator v3.1 Cycle Sequencing kit (PE Applied Biosystems) and the ABI3730 Sequencer.
Haplotype Analysis
A Bayesian statistical method implemented in PHASE version 2.1 was used to construct phased haplotypes from phase-unknown genotype data. 24 LD between all of the possible pairs of loci was calculated using EM estimation of haplotype frequencies and LD calculation, available online at http://request.mdacc.tmc.edu/Ϸqhuang/Software/pub.htm.
Genotyping of BRIGHT Study for ؊1889 G/T and ؊1859 A/G
A subset of the BRIGHT Study population (nϭ512) was genotyped for the Ϫ1889 G/T and Ϫ1859 A/G SNPs using a nested PCR method to increase specificity, followed by sequencing. In both reactions, a heat-activated thermostart Taq polymerase (Abgene) was used. Please see the online supplement for the sequences of the primers used in both reactions.
Urinary Corticosteroid Metabolite Measurements
Urine samples (24-hour) were collected in plain plastic containers without preservative. Aliquots of urine were stored at Ϫ20°C. Excretion rates of steroid metabolites were measured by gas chromatography/mass spectrometry using the method of Shackleton 25 with minor modifications. The ratio of tetrahydrodeoxycortisol (THS)/total cortisol (total F) was used as an index of 11␤-hydroxylase activity.
In Vitro Expression Studies
Site-Directed Mutagenesis
The 5Ј regulatory region (1937bp) of CYP11B1 was cloned into the pGL3 basic vector (Promega Corp). The CYP11B1 Ϫ1889 G/T and Ϫ1859 A/G SNPs were constructed in vitro using this pGL3/B1 5Јregulatory region construct. Site-directed mutagenesis was performed using the Quick-Change site-directed mutagenesis kit (Stratagene Ltd) following the protocol described previously. 26 Please see the online supplement for the sequences of the primers used. The entire insert in each case was sequenced to confirm the presence of the desired mutations and that no unwanted base changes had been incorporated.
Cell Culture and Transfection
Y-1 mouse adrenal cells (American Type Culture Collection) were cultured at 37°C in 5% CO 2 in F-12K Nutrient Mixture, Kaighn's Modification (GIBCO) supplemented with 15% horse serum (GIBCO), 2.5% fetal bovine serum (Sigma-Aldrich), and 1% penicillin/streptomycin (GIBCO). Cells were plated at 3.5ϫ10 5 cells per well in 6-well plates and incubated for 24 hours before transfection. Transfection was carried out using 6 L of Fugene (Roche Diagnostics) and 1 g of Wt or mutant plasmid in MEM/Eagle's medium(2 ml) for 42 hours. The pSV-␤-galactosidase control vector (0.04 g; Promega Corp) was added as a marker of transfection efficiency. After transfection, the cells were treated with agonists (forskolin 10 mol/L or ACTH 1 mol/L) for 6 hours. The cells were then lysed and luciferase activity measured according to the manufacturer's protocols (Promega Corp). Protein (BCA assay, Pierce Biotechnology) and ␤-galactosidase activity (Promega Corp) measurements were used to determine cell number and transformation efficiency, and the luciferase results were corrected appropriately.
Statistics
A 2 test was used to determine whether the allele frequencies of Ϫ1889 G/T and Ϫ1859 A/G within the BRIGHT subgroup were in Hardy-Weinberg equilibrium. Steroid excretion data did not follow a normal distribution and so were compared by nonparametric methods (Mann-Whitney test). The in vitro expression results for each construct were compared with the appropriate control using a 2-sample t test. In all instances, a P value of Ͻ0.05 was accepted as significant.
Results
Polymorphism Detection
Twenty-six subjects, from the normotensive MONICA population, already genotyped and homozygous for Ϫ344 C/T and intron Conv variants (TT/ConvConv [nϭ10], CC/WtWt [nϭ10], and TT/WtWt [nϭ6]), were screened for polymorphisms. A total of 83 biallelic polymorphisms were identified across the entire CYP11B locus (44 631 bp) that showed association with Ϫ344 C/T and intron Conv variants in CYP11B2 (Figure 1 ). Of the 83 polymorphisms, 64 were located within the CYP11B2 gene, and 19 were located within the CYP11B1 gene. The polymorphisms were spread throughout the gene exons, introns, and the adjacent upstream and downstream regions, with the highest frequency being located in intronic regions.
CYP11B2 Polymorphisms
Sixty-four variants were identified in CYP11B2 that are in LD with the Ϫ344 C/T and intron Conv variants (Figure 1) . Most of these changes were part of the intron Conv variant in intron 2. Of the remainder, 3 single base substitutions were 
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Polymorphic Variation in the CYP11B1 Genefound in exons 3 and 6. Two of these are synonymous changes with no effect on amino acid sequence: Phe168Phe and Arg374Arg. These mutations have been described previously by the National Center for Biotechnology Information, accessible on the dbSNP website (http://ncbi.nlm.nih.gov/ SNP), with the identification numbers rs4546 and rs4538, respectively. The third, at codon 173 (rs4539), does cause an amino acid change from Lys to Arg but has been shown to have no effect on aldosterone synthase activity in vitro. [27] [28] Seven single base substitutions were also identified within the 5Ј regions immediately upstream of the CYP11B2 gene.
CYP11B1 Polymorphisms
Nineteen variants were identified in CYP11B1 that show association with the Ϫ344 C/T and intron Conv variants in CYP11B2 ( Figure 1) . As with CYP11B2, most of these were within intronic regions (introns 2 through 6 and 8). Two SNPs that were identified in exons 1 (Leu75Leu) and 2 (Asp82Asp) have been described previously (National Center for Biotechnology Information rs6410 and rs5283, respectively). Two novel SNPs were identified within the 5Јregulatory region at positions Ϫ1889 (G/T) and Ϫ1859 (A/G) upstream of the ATG start codon. These SNPs are in LD with the T/Conv haplotype in CYP11B2 (Figure 2) .
Because of their potential to alter CYP11B1 gene transcription, the Ϫ1889 G/T and Ϫ1859 A/G SNPs were identified as key functional candidates to account for the impaired 11␤-hydroxylase efficiency associated previously with the Ϫ344 T and the intron 2 Conv alleles.
Haplotype Analysis
Haplotype analysis revealed 9 haplotypes that have frequencies Ͼ1% and describe 75% of chromosomes in the data set. Four of these common haplotypes each have a frequency of Ͼ5% and, in combination, account for 68% of chromosomes in the data set ( Figure 2 ). These haplotypes are conserved across the entire region, confirming that there is strong LD across the locus, with a DЈ value of Ϸ0.75 to 1.0 and an r 2 value of Ϸ0.5 to 1.0.
Genotyping of BRIGHT Study for ؊1889 G/T and ؊1859 A/G
To determine whether the Ϫ1889 G/T and Ϫ1859 A/G SNPs associate with 11␤-hydroxylase efficiency, their frequency and phenotypic associations were investigated in the hypertensive BRIGHT population.
Demographic Data for BRIGHT Subgroup
Blood pressure and other relevant demographic data are shown in Table 1 ; the population was significantly hypertensive but not significantly overweight. The only significant difference in characteristics of subject groups separated according to the Ϫ1889 (GG versus TT Pϭ0.015) or Ϫ1859 (AA versus GG Pϭ0.013) SNPs was with waist/hip ratio.
Genetic Analysis of CYP11B1
The frequencies of the Ϫ1889 and Ϫ1859 SNPs are illustrated in Table 2 (Ϫ1889 G: 
Association With THS/Total F Metabolites
The major urinary corticosteroid metabolites examined (tetrahydrocortisol, (allo)tetrahydrocortisol, tetrahydrocortisone, dehydroepiandrosterone, aetiocholanolone, tetrahydroaldosterone, and tetrahydrodeoxycortisol) are listed in Table 3 . There was no significant difference in total F metabolite excretion rate (micrograms per 24 hours) between the Ϫ1889 G/T (Pϭ0.4513) or Ϫ1859 A/G (Pϭ0.2789) genotypes. The THS/total F ratio (index of 11␤-hydroxylase activity) was significantly higher in Ϫ1889 TT homozygotes than in GG homozygotes (Pϭ0.024). A similar pattern was seen with the Ϫ1859 SNP, with GG homozygotes tending to have a higher ratio than AA homozygotes (Pϭ0.056; Table 3 ). There was no statistically significant difference between the Ϫ1889 TT and GT groups, but the THS/F ratio remained significantly higher in the heterozygous group than the GG subjects (Pϭ0.019). A similar pattern is seen for Ϫ1859, with no statistical difference between the GG and AG groups but a trend to a higher ratio in the heterozygous group than the AA homozygotes (Pϭ0.066).
In Vitro Expression Studies
To investigate whether the altered 11␤-hydroxylase efficiency associated with the Ϫ1889 G/T and Ϫ1859 A/G SNPs in the BRIGHT population is because of an altered transcriptional response, the effects of these variants on reporter gene expression were analyzed in vitro. The impact of the Ϫ1889 G/T and Ϫ1859 A/G single base changes on gene expression using luciferase reporter gene constructs revealed no significant effect on basal expression levels. The construct containing the Ϫ1889 T and the Ϫ1859 G alleles has a significantly reduced response to stimulation with either 1 mol/L of ACTH (PϽ0.001) or 10 mol/L of forskolin (Pϭ0.036) when compared with the contrasting allele combination (Figure 3 ).
Discussion
The CYP11B1/2 locus is of particular interest as a key candidate region for cardiovascular disease. Previous studies have examined whether polymorphisms associated with CYP11B2 are involved in essential hypertension. We and others have reported that variation at Ϫ344 C/T is associated with increased aldosterone and increased blood pressure, 9 -12 but not all groups have been able to confirm this. [13] [14] [15] [16] However, we and others have found a very consistent association with good biochemical evidence of altered 11␤-hydroxylation efficiency, which draws attention to the homologous gene CYP11B1. 17, 18, 20, 21, 29 The importance of this locus has been demonstrated previously in the Dahl saltsensitive rat model of hypertension in which mutations in CYP11B1 account for the biochemical and hemodynamic abnormalities. 30, 31 For these reasons, in the current study, we have investigated in greater detail the pattern of variation across the region. We now demonstrate that the overall sequence variation across the CYP11B locus is high, consistent with previous reports. 32, 33 Recent work has demonstrated that the Ϫ344C/T and intron Conv variants in CYP11B2 are in LD with SNPs in CYP11B1, specifically in exon 1 (225 G/A and Leu75Leu), intron 3 (2803 A/G), and intron 6 (4265 G/A). 20, 21 We have demonstrated previously that an increased THS excretion was correlated with haplotypes carrying the Ϫ344 T allele and that the strongest association was with the Leu75Leu SNP in CYP11B1. However, this is a conservative change and is unlikely to be functional. In the present study we have demonstrated that there is tight LD across the entire CYP11B locus. This is confirmed by the presence of relatively few common haplotypes, with 4 (each with a frequency Ͼ5%) accounting for 68% of chromosomes in the data set. Our detailed sequencing identified several candidate variants that could account for the observed phenotypes associated previously with the Ϫ344C/T and intron Conv variants in CYP11B2. Several of these were identified in CYP11B2, and it is possible that one (or more) may contribute to the increased aldosterone levels that have been associated previously with the T/Conv haplotype. 9 -12 This is currently being investigated.
However, of particular interest to this study is that the Ϫ344C/T and intron Conv variants in CYP11B2 were shown to be in strong LD with several genetic variants in CYP11B1. Of the 19 variants identified in CYP11B1 that are in LD with Ϫ344 C/T and intron Conv, only 2 were located within the coding sequence, and both of these were synonymous changes (Leu75Leu and Asp82Asp). As in CYP11B2, the majority of variants identified in CYP11B1 were in intronic regions. However, 2 novel SNPs were identified in the 5Ј regulatory region upstream of the CYP11B1 gene at positions Ϫ1889 G/T and Ϫ1859 A/G. These may alter transcriptional regulation of the CYP11B1 gene and, therefore, contribute the observed biochemical phenotype of decreased 11␤-hydroxylation.
To investigate whether the Ϫ1889 G/T and Ϫ1859 A/G SNPs do indeed associate with altered 11␤-hydroxylation, we genotyped a subgroup from the BRIGHT hypertension study for both of these SNPs. Our data demonstrate a significant association between these SNPs and the ratio of THS/total F, the index of impaired 11␤-hydroxylase efficiency. Those subjects homozygous for the Ϫ1889 T allele showed lower 11␤-hydroxylation efficiency (increased urinary THS/total F ratio) than those homozygous for the G allele. Similarly, subjects homozygous for the Ϫ1859 G allele showed a trend toward a reduced 11␤-hydroxylation efficiency than those homozygous for the A allele, although this did not quite reach statistical significance. As mentioned previously, it is these alleles (Ϫ1889 T and Ϫ1859 G) that are in LD with the CYP11B2 T/Conv haplotype. Importantly, there was no difference in urinary excretion of total cortisol metabolites between the 2 genotype groups for each SNP.
The effects of the Ϫ1889 G/T and Ϫ1859 A/G SNPs on gene transcription were tested in vitro using a luciferase reporter gene system. Compared with Wt (ie, Ϫ1889 G and Ϫ1859 A), constructs containing the Ϫ1889 T and Ϫ1859 G alleles reduced reporter gene activity by Ϸ50% in response to the agonists ACTH and the adenylate cyclase agonist forskolin, indicating decreased transcription. These data strongly support the theory that the reduced 11␤-hydroxylation associated previously with the T/Conv haplotype in CYP11B2 is accounted for by variants in CYP11B1, such as Ϫ1889 T and Ϫ1859 G. The is one of the first studies in humans to identify novel genetic variants in a candidate gene for hypertension, which not only associate with an intermediate phenotype but have also been shown to have functional effects on gene transcription in vitro.
Perspectives
Evidence of a slightly reduced 11␤-hydroxylase efficiency is a consistent feature of subjects with essential hypertension compared with normotensive control subjects. 34 -36 This study demonstrates that the Ϫ1889 G/T and Ϫ1859 A/G SNPs in CYP11B1, which associate with reduced 11␤-hydroxylase efficiency, are in LD with those variants in CYP11B2 that associate with higher aldosterone levels. How the 2 effects are related is currently being investigated.
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